Tracking defects caused by brain tumor mutation yields insight to advance targeted therapy

8 mayo 2015

Scientists have gained ground toward developing more targeted therapies for the most common childhood brain tumor. The findings involve the DDX3X gene. In 2012, other work highlighted DDX3X as a promising focus for efforts to develop targeted therapies against medulloblastoma. Such treatments target the genetic mistakes that give rise to the brain tumor’s four subtypes.